weight

Hypoglycemia and diabetes: a report of a workgroup of the american diabetes association and the endocrine society.

Seaquist, Elizabeth R; Anderson, John; Childs, Belinda; Cryer, Philip; Dagogo-Jack, Samuel; Fish, Lisa; Heller, Simon R; Rodriguez, Henry; Rosenzweig, James; Vigersky, Robert

Diabetes care; 2013 May;36(5):1384-95. PMID: 23589542;

Category: General Reviews;

Tags: beta cell pathophysiology, glycemic control, insulin therapy, sulfonylureas (SUs), weight

Year in Diabetes 2012: The Diabetes Tsunami

R. Sherwin and A. M. Jastreboff

Journal of Clinical Endocrinology and Metabolism

Category: General Reviews;

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Challenges of Accelerating Treatment to Get to Goal

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

The Evolving Role of the Endocrinologist and Primary Care Doctor in Establishing Goals of Care

Posted August 23, 2012 by John L. Leahy, MD

Tags: glycemic control, lifestyle changes, weight

Listen to the Podcast and/or read the transcript.

1 Comment

The Evolving Role of the Endocrinologist and Primary Care Doctor in Establishing Goals of Care

Tags: glycemic control, weight

Combination Therapies and Intensification of Therapy

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Treatment failure, Non-responders, and Non-adherence

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Podcast: A Discussion About 2012 ADA/EASD Position Statement

Posted August 2, 2012 by Doron Schneider, MD, FACP

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Listen to the Podcast and/or read the transcript.

Add new comment

A Discussion About the 2012 ADA/EASD Position Statement

Tags: GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Dr. Doron Schneider and Dr. Jack Leahy discuss the 2012 ADA/EASD position statement on management of type 2 diabetes and its implications to clinical care.

The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position Statement

Posted June 6, 2012 by John L. Leahy, MD

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, prediabetes, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

In my last blog, I explained why I’m not a fan of the highly awaited ADA/EASD position statement on management of type 2 diabetes,

Betacell

A resource for physicians established by the Endocrine Society

Text Size:

About Topics

Hypoglycemia and diabetes: a report of a workgroup of the american diabetes association and the endocrine society.

Year in Diabetes 2012: The Diabetes Tsunami

Challenges of Accelerating Treatment to Get to Goal

The Evolving Role of the Endocrinologist and Primary Care Doctor in Establishing Goals of Care

The Evolving Role of the Endocrinologist and Primary Care Doctor in Establishing Goals of Care

Combination Therapies and Intensification of Therapy

Treatment failure, Non-responders, and Non-adherence

Podcast: A Discussion About 2012 ADA/EASD Position Statement

A Discussion About the 2012 ADA/EASD Position Statement

The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position Statement